Pharmacological prioritisation of signals of disproportionate reporting: Proposal of an algorithm and pilot evaluation

European Journal of Clinical Pharmacology

Volumn 70, Issue 5, 2014, Pages 617-625

  Salvo, Francesco ^a,b   Raschi, Emanuel ^c   Moretti, Ugo ^d   Chiarolanza, Anita ^c   Fourrier Réglat, Annie ^a,b,e   Moore, Nicholas ^a,b,e   Sturkemboom, Miriam ^f   De Ponti, Fabrizio ^c   Poluzzi, Elisabetta ^c   Pariente, Antoine ^a,b,e  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b BORDEAUX UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d UNIVERSITY OF VERONA   (Italy)

^e Centre of Clinical Investigation Clinical Epidemiology   (France)

^f ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Disproportionality; Signal detection; Signal prioritisation; Spontaneous reporting

Indexed keywords

AMOXAPINE; ATYPICAL ANTIPSYCHOTIC AGENT; CINNARIZINE; ENALAPRIL; FLUNARIZINE; FLUPENTIXOL; INDORAMIN; KETAMINE; LOXAPINE; MEMANTINE; MEPIVACAINE; METOCLOPRAMIDE; METOPIMAZINE; MISOPROSTOL; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE INHIBITOR; OXETORONE; PAROXETINE; PHENOTHIAZINE DERIVATIVE; PIMOZIDE; PIPERAZINE DERIVATIVE; RANOLAZINE; SEROTONIN 3 ANTAGONIST; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SULPIRIDE; THIORIDAZINE; TRIMETAZIDINE; UNINDEXED DRUG; VALPROMIDE; VERALIPRIDE;

ALGORITHM; ARTICLE; DATA BASE; DATA MINING; DELPHI STUDY; DRUG DATABASE; DRUG SURVEILLANCE PROGRAM; EVALUATION STUDY; EXTRAPYRAMIDAL SYNDROME; HUMAN; INFORMATION PROCESSING; PHARMACOLOGICAL PROCEDURES; PILOT STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; SCORING SYSTEM; SIGNALS OF DISPROPORTIONATE REPORTING; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FACTUAL DATABASE; MEDICAL INFORMATICS; ORGANIZATION AND MANAGEMENT; PROCEDURES; RISK; STATISTICS AND NUMERICAL DATA;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ALGORITHMS; DATA MINING; DATABASES, FACTUAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; MEDICAL INFORMATICS COMPUTING; ODDS RATIO; PILOT PROJECTS;

EID: 84898840108     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-014-1657-2     Document Type: Article

References (30)

1. Moore N (2013) The past, present and perhaps future of pharmacovigilance: homage to Folke Sjoqvist. Eur J Clin Pharmacol 69(Suppl 1):33-41. doi: 10.1007/s00228-013-1486-8
2. Moore N, Thiessard F, Begaud B (2005) The history of disproportionality measures (reporting odds ratio, proportional reporting rates) in spontaneous reporting of adverse drug reactions. Pharmacoepidemiol Drug Saf 14(4):285-286. doi: 10.1002/pds.1058
3. Avillach P, Salvo F, Thiessard F, Miremont-Salame G, Fourrier-Reglat A, Haramburu F, Begaud B, Moore N, Pariente A, on behalf of l'Association des Centres Regionaux de P (2013) Pilot evaluation of an automated method to decrease false-positive signals induced by co-prescriptions in spontaneous reporting databases. Pharmacoepidemiol Drug Saf. doi: 10.1002/pds.3454
4. Pariente A, Avillach P, Salvo F, Thiessard F, Miremont-Salame G, Fourrier-Reglat A, Haramburu F, Begaud B, Moore N, Association Francaise des Centres Regionaux de P (2012) Effect of competition bias in safety signal generation: analysis of a research database of spontaneous reports in France. Drug Saf 35(10):855-864. doi: 10.2165/11631780-000000000-00000 5
5. Salvo F, Leborgne F, Thiessard F, Moore N, Begaud B, Pariente A (2013) A potential event-competition bias in safety signal detection: results from a spontaneous reporting research database in france. Drug Saf 36(7):565-572. doi: 10.1007/s40264-013-0063-5
6. Ahmed I, Dalmasso C, Haramburu F, Thiessard F, Broet P, Tubert-Bitter P (2010) False discovery rate estimation for frequentist pharmacovigilance signal detection methods. Biometrics 66(1):301-309. doi: 10.1111/j.1541-0420.2009. 01262.x
7. Maignen F, Hauben M, Hung E, Van Holle L, Dogne JM (2013) Assessing the extent and impact of the masking effect of disproportionality analyses on two spontaneous reporting systems databases. Pharmacoepidemiol Drug Saf. doi: 10.1002/pds.3529
8. Juhlin K, Ye X, Star K, Noren GN (2013) Outlier removal to uncover patterns in adverse drug reaction surveillance - a simple unmasking strategy. Pharmacoepidemiol Drug Saf 22(10):1119-1129. doi: 10.1002/pds.3474
9. Hauben M, Reich L (2005) Communication of findings in pharmacovigilance: use of the term "signal" and the need for precision in its use. Eur J Clin Pharmacol 61(5-6):479-480. doi: 10.1007/s00228-005-0951-4
10. Aronson JK, Hauben M, Bate A (2012) Defining 'surveillance' in drug safety. Drug Saf 35(5):347-357. doi: 10.2165/11597590-000000000-00000
11. Lindquist M (2007) Use of triage strategies in the WHO signal-detection process. Drug Saf 30(7):635-637
12. Levitan B, Yee CL, Russo L, Bayney R, Thomas AP, Klincewicz SL (2008) A model for decision support in signal triage. Drug Saf 31(9):727-735
13. Seabroke S, Wise L, Waller P (2013) Development of a novel regulatory pharmacovigilance prioritisation system: an evaluation of its performance at the UK Medicines and Healthcare products Regulatory Agency. Drug Saf 36(10):1025-1032. doi: 10.1007/s40264-013-0081-3
14. Heeley E, Waller P, Moseley J (2005) Testing and implementing signal impact analysis in a regulatory setting: results of a pilot study. Drug Saf 28(10):901-906
15. Waller P, Heeley E, Moseley J (2005) Impact analysis of signals detected from spontaneous adverse drug reaction reporting data. Drug Saf 28(10):843-850
16. Poluzzi E, Raschi E, Koci A, Moretti U, Spina E, Behr ER, Sturkenboom M, De Ponti F (2013) Antipsychotics and torsadogenic risk: signals emerging from the US FDA Adverse Event Reporting System database. Drug Saf 36(6):467-479. doi: 10.1007/s40264-013-0032-z
17. Molokhia M, De Ponti F, Behr ER, Trifiro G, Sturkenboom M, Consortium A (2012) Academic output from EU-funded health research projects. Lancet 380(9857):1903-1904. doi: 10.1016/S0140-6736(12)62103-5
18. Dalkey N, Helmer O (1963) An experimental application of the DELPHI method to the use of experts. Managmenet Sci 9:458-467
19. Definitions of terms for reporting adverse drug reactions (IX): nervous system and psychiatric disorders (1998). Pharmacoepidemiol Drug Saf 7 (1):39-49. doi:10.1002/(sici)1099-1557(199801/02)7:139::aid-pds316∈>∈3.0. co;2-z
20. MedDRA Maintenance and Support Services Organization. Introductory Guide to Standardised MedDRA Queries (SMQs) Version 15.0. (2012) International Federation of Pharmaceutical Manufacturers and associations. www.meddra.org/sites/default/files/guidance/file/smq-intguide-15-0-english.pdf.
21. van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC (2002) A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 11(1):3-10. doi: 10.1002/pds.668
22. Ahmed I, Haramburu F, Fourrier-Reglat A, Thiessard F, Kreft-Jais C, Miremont-Salame G, Begaud B, Tubert-Bitter P (2009) Bayesian pharmacovigilance signal detection methods revisited in a multiple comparison setting. Stat Med 28(13):1774-1792. doi: 10.1002/sim.3586
23. Brunton LL, Chabner B, Knollman BrC, Goodman LSPbot (2011) Goodman & Gilman's The pharmacological basis of therapeutics. 12th ed. / editor, Laurence L. Brunton; associate editors, Bruce A. Chabner, Bjorn C. Knollmann. edn. McGraw-Hill, New York, N.Y.; London
24. Harpaz R, DuMouchel W, LePendu P, Bauer-Mehren A, Ryan P, Shah NH (2013) Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system. Clin Pharmacol Ther 93 (6):539-546. doi: 10.1038/clpt.2013.24 clpt201324 [pii]
25. Caster O, Noren GN, Madigan D, Bate A (2013) Logistic Regression in Signal Detection: Another Piece Added to the Puzzle. Clin Pharmacol Ther. doi: 10.1038/clpt.2013.107
26. ANSM (2013) Agence Nationale de Sécurité du Medicament et des Produits de Santé. Retrait de l'autorisation de mise sur le marché du Vidora 25 mg (indoramine) -Point d'information. http://ansm.sante.fr/S-informer/Actualite/Retrait-de-l-autorisation-de-mise-sur- le-marche-du-Vidora-25-mg-indoramine-Point-d-information. Accessed 03/06/2013
27. ANSM (2012) Agence Nationale de Sécurité du Medicament et des Produits de Santé. Restriction des indications des spécialités à base de trimétazidine (Vastarel® et génériques) - Point d'information. http://ansm.sante.fr/S- informer/Points-d-information-Points-d-information/Restriction-des-indications- des-specialites-a-base-de-trimetazidine-Vastarel-R-et-generiques-Point-d- information. Accessed 03/06/2013
28. Cha DS, McIntyre RS (2012) Treatment-emergent adverse events associated with atypical antipsychotics. Expert Opin Pharmacother 13(11):1587-1598. doi: 10.1517/14656566.2012.656590
29. Madhusoodanan S, Alexeenko L, Sanders R, Brenner R (2010) Extrapyramidal symptoms associated with antidepressants - a review of the literature and an analysis of spontaneous reports. Ann Clin Psychiatry 22(3):148-156
30. Kapur S, Cho R, Jones C, McKay G, Zipursky RB (1999) Is amoxapine an atypical antipsychotic? Positron-emission tomography investigation of its dopamine2 and serotonin2 occupancy. Biol Psychiatry 45(9):1217-1220